A Phase 2 interventional study of LDE225 in Acute Leukemias, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Leukemia, Myeloid, Acute by Novartis — none open to participants now, 3 under way, none of them phase 3. Leukemia, Myeloid, Acute · Novartis.
Among the 40 studies in Leukemia, Myeloid, Acute by Novartis, this one is the 15th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 2, and was the 14th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 40 studies in Leukemia, Myeloid, Acute by Novartis is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 20 · Phase 3 2 · Phase 4 2
First in 1999; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 64 across the 36 interventional studies, 81 across the 1 observational. Of the 31 that completed or were terminated, 20 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Leukemia, Myeloid, Acute by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
Drug: LDE225
Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
Drug: LDE225
LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
Rate of Complete Remission (CR)
Complete Response (CR) was based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CR. A treatment cycle was defined as 4 weeks. The outcome measure for the study is based on standardized response criteria as defined by the International Working Group (IWG) for AML. The IWG was established by a group of investigators interested in the design and conduct of clinical trials in acute myeloid leukemia (AML). The criteria established by this group (a set of recommendations for response assessment) are well established, endorsed by major institutions and Health Authorities, and are widely used in clinical trials. No statistical analysis was planned for this primary outcome.
Time frame: at screening, every week up to Week 9, every 2 weeks thereafter until CR, every 4 weeks after CR up to 24 months
Complete Remission With Incomplete Blood Count Recovery (CRi)
The other primary efficacy endpoint was CRi based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CRi. A treatment cycle was defined as 4 weeks. No statistical analysis was planned for this primary outcome.
Time frame: within 3 days after clearance of blasts from peripheral blood (PB), monthly thereafter until CR or reappearance of blasts in the PB, after CR every other month until discontination up to 24 months
Overall Response Rate (ORR)
ORR was the rate of complete remission (CR), complete remission with incomplete blood count recovery (CRi) or partial response (PR) according to IWG criteria. CR, CRi or PR will be assessed through bone marrow biopsy/aspirate and peripheral blood blasts counts.
Time frame: Every 8 weeks for the first 6 months and every 12 weeks until 53 weeks after the last patient is enrolled or until relapse up to 24 months
Parmacokintics (PK) Parameter: Cmax
Cmax is the maximum observed plasma concentration after drug administration.The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the pharmacokineticist. Cmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
Time frame: Week 1 Day 1, Week 9 Day 1
Parmacokintics (PK) Parameter: Tmax
Tmax is the time to reach Cmax. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. Tmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
Time frame: Week 1 Day 1,Week 9 Day 1
Parmacokintics (PK) Parameter: AUC0-8h
AUC0-8h is the area under the concentration-time curve from time zero to 8 hours. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-8h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
Time frame: Week 1 Day 1,Week 9 Day 1
Parmacokintics (PK) Parameter: AUC0-24h
AUC0-24 is the area under the concentration-time curve from time zero to 24 hours done only on 800 mg once a day schedule. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-24h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
Time frame: Week 1 Day 1,Week 9 Day 1
| Milestone | LDE225-400 | LDE225-800 |
|---|---|---|
| Started | 35 | 34 |
| Untreated | 0 | 1 |
| Treated | 35 | 34 |
| Completed | 0 | 0 |
| Not completed | 35 | 34 |
| Withdrew: Adverse event | 7 | 6 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Progressive disease | 22 | 21 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
| Withdrew: Subject/guardian decision | 2 | 3 |
Complete Response (CR) was based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CR. A treatment cycle was defined as 4 weeks. The outcome measure for the study is based on standardized response criteria as defined by the International Working Group (IWG) for AML. The IWG was established by a group of investigators interested in the design and conduct of clinical trials in acute myeloid leukemia (AML). The criteria established by this group (a set of recommendations for response assessment) are well established, endorsed by major institutions and Health Authorities, and are widely used in clinical trials. No statistical analysis was planned for this primary outcome.
| Participants | LDE225-400 | LDE225-800 |
|---|---|---|
| Rate of Complete Remission (CR) | 0 | 0 |
The other primary efficacy endpoint was CRi based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CRi. A treatment cycle was defined as 4 weeks. No statistical analysis was planned for this primary outcome.
| Participants | LDE225-400 | LDE225-800 |
|---|---|---|
| Complete Remission With Incomplete Blood Count Recovery (CRi) | 1 | 0 |
ORR was the rate of complete remission (CR), complete remission with incomplete blood count recovery (CRi) or partial response (PR) according to IWG criteria. CR, CRi or PR will be assessed through bone marrow biopsy/aspirate and peripheral blood blasts counts.
| Participants | LDE225-400 | LDE225-800 |
|---|---|---|
| Overall Response Rate (ORR) | 1 | 0 |
Cmax is the maximum observed plasma concentration after drug administration.The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the pharmacokineticist. Cmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
| ng/mL | LDE225-400 | LDE225-800 |
|---|---|---|
| Week 1 Day 1 | 237 ± 158 | 343 ± 275 |
| Week 9 Day 1(n: 7, 7) | 1640 ± 612 | 1500 ± 874 |
Tmax is the time to reach Cmax. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. Tmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
| hr | LDE225-400 | LDE225-800 |
|---|---|---|
| Week 1 Day 1 | 2.13 ± NA | 2.12 ± NA |
| Week 9 Day 1 (n: 7, 7) | 1.88 ± NA | 2.02 ± NA |
AUC0-8h is the area under the concentration-time curve from time zero to 8 hours. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-8h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
| ng*hr/mL | LDE225-400 | LDE225-800 |
|---|---|---|
| Week 1 Day1 | 988 ± 542 | 1560 ± 1230 |
| Week 9 Day1 (n: 7, 7) | 9750 ± 2830 | 7910 ± 5090 |
AUC0-24 is the area under the concentration-time curve from time zero to 24 hours done only on 800 mg once a day schedule. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-24h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.
| ng*hr/mL | LDE225-400 | LDE225-800 |
|---|---|---|
| Week 1 Day 1 | 0 ± 0 | 3110 ± 2620 |
| Week 9 Day 1 (n: 7, 6) | 26500 ± 6650 | 24000 ± 11500 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDE225-400 | — | 25/35 (71.4%) | 35/35 (100%) |
| LDE225-800 | — | 25/34 (73.5%) | 34/34 (100%) |
| Event | LDE225-400 | LDE225-800 |
|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 9/35 | 7/34 |
| PYREXIAGeneral disorders | 1/35 | 4/34 |
| SEPSISInfections and infestations | 2/35 | 4/34 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 4/35 | 1/34 |
| PNEUMONIAInfections and infestations | 3/35 | 3/34 |
| ANAEMIABlood and lymphatic system disorders | 0/35 | 2/34 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 2/35 | 2/34 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 1/35 | 2/34 |
| ASTHENIAGeneral disorders | 2/35 | 1/34 |
| LUNG INFECTIONInfections and infestations | 2/35 | 0/34 |
| Event | LDE225-400 | LDE225-800 |
|---|---|---|
| VOMITINGGastrointestinal disorders | 7/35 | 12/34 |
| NAUSEAGastrointestinal disorders | 11/35 | 10/34 |
| FATIGUEGeneral disorders | 8/35 | 10/34 |
| PYREXIAGeneral disorders | 7/35 | 10/34 |
| CONSTIPATIONGastrointestinal disorders | 6/35 | 8/34 |
| DIARRHOEAGastrointestinal disorders | 7/35 | 8/34 |
| MYALGIAMusculoskeletal and connective tissue disorders | 4/35 | 8/34 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 8/35 | 7/34 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 8/35 | 5/34 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 7/35 | 5/34 |
Full analysis set (FAS): comprised of all patients who were randomized to a study treatment. According to the intent-to-treat principle, patient data were analyzed according to the treatment to which they had been randomized.
| Age, Continuous(Years) | LDE225-400 | LDE225-800 | Total |
|---|---|---|---|
| Mean | 65.3 ± 12.31 | 67.7 ± 11.65 | 66.5 ± 11.96 |
| Sex: Female, Male(Participants) | LDE225-400 | LDE225-800 | Total |
|---|---|---|---|
| Female | 18 | 13 | 31 |
| Male | 17 | 22 | 39 |
The record gives a start of May 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib